Get informed when a big investor buys or sells
+ Follow-88.46%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Atea Pharmaceuticals (AVIR) currently reports a ROE of -88.46%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Atea Pharmaceuticals's ROE history and peer comparisons.
Atea Pharmaceuticals's ROE of -88.46% is lower than the Healthcare sector average of 13.1%. That is roughly 775.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Atea Pharmaceuticals's current -88.46% should be judged against Healthcare norms (sector average: 13.1%) and against AVIR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -88.46%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Atea Pharmaceuticals, and consider following AVIR for alerts when major investors trade the stock.
Atea Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -88.46% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVIR with unrelated industries.